Abstract:OBJECTIVE To fuse human hepatocellular carcinoma (HCC) cells with mature monocyte-derived dendritic cells (FastDC) and to observe in vitro the function of the fused cells in stimulating autologous T cells proliferation and inducing HCC-specific cytotoxic T lymphocyte (CTL) response. METHODS CD14(+) cells were isolated and purified from the peripheral blood of a healthy HLA-A2 blood donor and cultured in fresh dendritic cell complete medium for 24 h, then proinflammatory mediators were supplemented for another 24 h, thus generating mature dendritic cell (FastDCs). The FastDCs were fused with human HCC cells of the line HCCLM3 to generate novel dendritoma. T cells were isolated from selected CD14(-) cells and then divided into 4 groups to be stimulated with dendritoma cells, DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells respectively for 96 hours. 18 hours before the end of cultivation (3)H-TdR was added into the culture fluid. Scintillation counter was used to measure the cpm values. CD8(+)T cells were isolated from CD14(-) cells, and added with different stimulating cells radiated by (60)Co and IL-2, IL-6, and IL-7. The values of IFN-gamma in the supernatants of the culture fluid of CD8(+)T cells with dendritoma cells, DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells was measured. HCCLM3, K562, HLE, self monocytes labeled with Na(2)(51)CrO(4) were added with effector cells, gamma-scintillation counter was used to measure the cpm value so as to calculate the killing ability of CTL. RESULTS The CTLs activated by dendritoma cells specifically killed the HCCLM3 cells in the context of MHC class I and acted less vigorously against the control target cells. The CTLs activated by dendritoma cells were stronger in killing HCCLM3 cells than DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells (all P < 0.05). The killing activity was decreased on the HCCLM3 cells incubated with anti-HLA-ABC antibody. Three, five, and seven days after co-cultivation the value of IFN-gamma in the supernatants of the culture fluid of CD8(+)T cells with fused cells, DCs, HCCLM3 cells, and mixed DCs-HCCLM3 cells increased gradually, especially in the supernatants of the culture fluid of CD8(+)T cells with dendritoma cells (400 pg/ml +/- 60 pg/ml 3 days after, 1030 pg/ml +/- 160 pg/ml 5 days after, and 1260 pg/L +/- 180 pg/L 7 days after). CONCLUSION The novel dendritomas formed with HCCLM3 cells and mature FastDCs from healthy human peripheral blood CD14(+) monocytes are potent stimulators for CD8(+)T cells in inducing HCCLM3 cell-specific lysis. With shorter time required for in vitro DC development, the rapid method of generation of dendritoma is more economic and may represent a new strategy for immunotherapy of hepatocellular carcinoma.

Eliciting specific antitumor immunity against hepatocellular carcinoma in vitro by fusions of HCC patient-derived dendritic cells with HCC cells

Antitumor Effect of Immunizations with Fusions of Dendritic and Hepatocellular Carcinoma Cells in Mice

A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

Antitumor Effect of Immunization with Fusion of Dendritic Cells and Hepatocellular Carcinoma Cells in Mice.

[Inducing Hepatocellular Carcinoma-Specific Cytotoxic T Lymphocyte Response Using Formed by Fusion of FastDCs and Allogeneic Human Hepatocellular Carcinoma Cells].

Dendritic Cells Pulsed with Α‐fetoprotein and Mutant P53 Fused Gene Induce Bi‐targeted Cytotoxic T Lymphocyte Response Against Hepatic Carcinoma

Effect of Dendritic Cell-Based Immunotherapy on Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Apoptosis Effect of Immunizations with Fusions of Dendritic Cells and HCC Cells in Mice

Induction of Specific Immune Response Against Hepatocellular Carcinoma by Human SLC and AFP Vector Transfected Dendritic Cells from CD34+ Hematopoietic Stem Cells

Improvement of the Cytotoxic T Lymphocyte Response Against Hepatocellular Carcinoma by Transduction of Cancer Cells with an Adeno-Associated Virus Carrying the Interferon-Γ Gene.

In Vitro Antitumor Immune Response Induced By Fusion Of Dendritic Cells And Colon Cancer Cells

Dendritic Cells Loaded with Ultrasound-Ablated Tumour Induce in Vivo Specific Antitumour Immune Responses

[Study on Immunoreaction Induced by DCs Loaded with Hepatocarcinoma Antigen Peptide In-Vitro].

An Experimental Study on the Antitumor Effects Induced by Fusions of Dendritic Cells with NCI-H460 Lung Cancer Cells

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

Immunotherapy of hepatocellular carcinoma with dendritic cells vaccine targeting to alpha-fetoprotein

Induction of Α-Fetoprotein-specific CD4- and CD8-mediated T-cell Response Using RNA-transfected Dendritic Cells

Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.

Improved Efficacy of Therapeutic Vaccination with Dendritic Cells Pulsed with Tumor Cell Lysate Against Hepatocellular Carcinoma by Introduction of 2 Tandem Repeats of Microbial HSP70 Peptide Epitope 407–426 and OK-432

Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.